Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer

We sought to investigate the impact of hormone receptor (HR) status and distant recurrence-free interval (DRFI) on the degree of overall survival (OS) benefit from palliative trastuzumab-containing treatment in HER2-positive metastatic breast cancer (MBC). Here, we retrospectively identified 588 eli...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Yang, Hai-Yuan, Ma, Ding, Liu, Yi-Rong, Hu, Xin, Zhang, Jian, Wang, Zhong-Hua, Di, Gen-Hong, Hu, Xi-Chun, Shao, Zhi-Ming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5430907/
https://ncbi.nlm.nih.gov/pubmed/28442763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-00663-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak